Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRF1 | P14222 | 4/20 | 0.64 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.52 |
| ▸ | GSK3B | P49841 | 2/20 | 0.52 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.52 |
| ▸ | PIM1 | P11309 | 1/20 | 0.52 |
| ▸ | FLT3 | P36888 | 1/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.52 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.51 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.51 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.51 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 6/20 | 0.49 |
| ▸ | PARP11 | Q9NR21 | 6/20 | 0.49 |
| ▸ | TARS1 | P26639 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 2/20 | 0.44 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.44 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2014718 | 0.86 | PRF1 (0.61) | PRF1CLK4GSK3BDAPK3NTRK1 | |
| SCHEMBL29952603 | 0.82 | CA12 (0.50) | PRF1CLK4GSK3BDAPK3NTRK1 | |
| SCHEMBL4610013 | 0.82 | CA12 (0.50) | PRF1CLK4GSK3BDAPK3NTRK1 | |
| SCHEMBL8167297 | 0.81 | CLK4 (0.75) | PRF1CLK4GSK3BDAPK3NTRK1 | |
| SCHEMBL10243599 | 0.79 | PARP10 (0.74) | PRF1CLK4GSK3BDAPK3NTRK1 | |
| SCHEMBL13680532 | 0.79 | CLK4 (0.78) | PRF1CLK4GSK3BDAPK3NTRK1 | |
| SCHEMBL14761055 | 0.79 | PRF1 (1.00) | PRF1 | |
| SCHEMBL14761053 | 0.79 | PRF1 (1.00) | PRF1 | |
| SCHEMBL14761057 | 0.79 | PRF1 (1.00) | PRF1 | |
| SCHEMBL14847348 | 0.75 | CLK4 (0.51) | PRF1CLK4GSK3BDAPK3NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065897-A1 | COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2013-03-14 | — | — | US | disclosed |
| EP-2515903-A1 | COMPOUNDS, PREPARATIONS AND USES THEREOF | Peter MacCallum Cancer Institute (AU) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011075784-A1 | COMPOUNDS, PREPARATIONS AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065897-A1 | COMPOUNDS, PREPARATION AND USES THEREOF | PRF1, GZMB, SERPINB1 | PRF1 1/4885CLK4 4804/4885GSK3B 3994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.